

Guidance for Industry

SPL Standard for Content of Labeling Technical Qs & As

DRAFT GUIDANCE

This Guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact Lonnie Smith 301-594-0011.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**October 2009
Electronic Submissions
Revision 1**

Guidance for Industry

SPL Standard for Content of Labeling

Technical Qs & As

Additional copies are available from:

*Office of Training and Communication
Division of Drug Information, HFD-240
Center for Drug Evaluation and Research
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573
<http://www.fda.gov/cder/guidance/index.htm>*

*Office of Communication, Outreach and
Development, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Rockville, MD 20852-1448
<http://www.fda.gov/cber/guidelines.htm>
Phone:
800-835-4709 or 301-827-1800*

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

October 2009
Electronic Submissions

Revision 1

1 **Guidance for Industry**¹

2 **SPL Standard for Content of Labeling**
3 **Technical Qs & As**
4

5
6 This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It
7 does not create or confer any rights for or on any person and does not operate to bind FDA or the public.
8 You can use an alternative approach if the approach satisfies the requirements of the applicable statutes
9 and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for
10 implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number
11 listed on the title page of this guidance.
12

13
14
15
16 **INTRODUCTION**

17
18 This guidance is intended to assist applicants who submit content of labeling to FDA as part of
19 a marketing application using the structured product labeling standard (SPL) in extensible
20 markup language (XML). The guidance also provides information to FDA staff who review and
21 manage product information using electronic systems. This is revision 1 of a guidance of the
22 same name that was issued in December 2005. The guidance has been revised to reflect changes
23 in the technology since 2005 and to harmonize the submission of SPL in the Center for
24 Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research
25 (CDER). We anticipate that additional guidance will be provided as new questions arise about
26 the use of SPL in different contexts.²
27

28 FDA's guidance documents, including this guidance, do not establish legally enforceable
29 responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should
30 be viewed only as recommendations, unless specific regulatory or statutory requirements are
31 cited. The use of the word *should* in Agency guidances means that something is suggested or
32 recommended, but not required.
33

34 **BACKGROUND**
35

36 In the *Federal Register* of December 11, 2003 (68 FR 69009), FDA published final regulations
37 requiring that the content of labeling be submitted to FDA electronically for new drug

¹ This guidance has been prepared by Office of Critical Path Programs in the Office of the Commissioner at the Food and Drug Administration.

² See FDA's guidance *Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing*.

Contains Nonbinding Recommendations

Draft — Not for Implementation

38 applications (NDAs), abbreviated new drug applications (ANDAs), certain biologics license
39 applications (BLAs),³ and annual reports (see 21 CFR 314.50(l), 314.94(d), 601.14(b), and
40 314.81(b), respectively). The regulations state that the content of labeling must be submitted to
41 FDA electronically and "in a form that FDA can process, review, and archive."
42

43 Initially, CDER accepted electronic submissions of content of labeling in portable document
44 format (PDF). Then, in September 2004, CDER announced that it would accept content of
45 labeling in both PDF and SPL formats until the autumn of 2005, when PDF would be eliminated.
46 On October 21, 2005, CDER announced in public docket number 92S-0251 that effective
47 October 31, 2005, CDER would no longer accept content of labeling submissions in PDF format
48 and that applicants should use the SPL standard when submitting content of labeling to FDA in
49 XML with original submissions, supplements, and annual reports. CBER made a similar
50 announcement on July 11, 2008, that went into effect on October 15, 2008. In a Draft Guidance
51 that published on July 10, 2008, CDER, CBER and the Center for Veterinary Medicine
52 announced their intention to begin using the SPL standard for electronic drug establishment
53 registration and drug product listing (a final version of that guidance was issued at the end of
54 May 2009).
55

56 Since FDA began accepting content of labeling in SPL format for application submissions, we
57 have received numerous questions about SPL submission requirements. Based on preliminary
58 questions, and in an effort to provide easy access to the answers to frequently asked questions,
59 in December 2005, we published the first guidance for industry *SPL Standard for Content of*
60 *Labeling Technical Qs and As*. In an effort to provide the most useful and up-to-date
61 information on SPL submissions, FDA is revising the December 2005 guidance. The revision
62 provides both updated answers to questions previously addressed and information responsive to
63 other questions related to submissions in SPL format. The Agency plans to continue updating
64 this guidance with additional answers to questions as warranted.

65 For definitions of SPL-related terms, please see FDA's Data Standards Council Web site at
66 www.fda.gov/oc/datacouncil. If you have additional questions about SPL submissions, you
67 should contact spl@fda.hhs.gov. For questions on submissions to CDER or CBER, contact the
68 appropriate electronic submission coordinator at esub@cder.fda.gov or esubprep@cber.fda.gov,
69 respectively. Specific questions pertaining to content of labeling should be directed to the
70 relevant review division or office in the appropriate center.

³ The final regulations do not apply to devices regulated under a BLA.

Contains Nonbinding Recommendations

Draft — Not for Implementation

71
72

TECHNICAL QUESTIONS AND ANSWERS

73 **1. What was the implementation date for using the SPL for content of labeling in FDA**
74 **application submissions?**

75 For CDER-regulated products, the implementation date was October 31, 2005. For CBER-
76 regulated products, the implementation date was October 15, 2008.

77 **2. When do I need to include an SPL file in my submission?**

78 An SPL file must accompany all submissions that propose changes to the content of labeling,
79 including certain amendments (e.g., an amendment to a “changes being effected” (CBE)
80 supplement containing updated content of labeling), submissions of final approved content of
81 labeling (regardless of marketing date), and annual reports (see question 34 for more
82 information on annual reports).⁴

83 **3. What if I have already submitted SPL content of labeling during the registration**
84 **and listing process?**

85
86 This guidance only applies to SPL files submitted with applications. Additional guidance has
87 been drafted that applies to the registration and listing process.⁵ If you have already submitted
88 identical content of labeling in a SPL file during the registration and listing process, you need not
89 include the SPL file in your application. Instead, we recommend that you update your
90 application by referencing the SPL file in the registration and listing system. To do this, place a
91 link in your application submission that directs FDA to your SPL file (e.g., “We have submitted
92 the SPL file with drug listing; it can be found at the following location
93 <http://www.accessdata.fda.gov/spl/data/> [insert your SPL document id root here/insert SPL
94 document id root here].xml”) (see also question 31).”

95
96 The SPL document ID has to be repeated in the URL for the users to be able to access the SPL
97 files from the Web server location.

98
99 **4. Do other labeling documents need to be provided using the SPL standard?**

100
101 No. Only electronic *content of labeling* is to be submitted using the SPL standard (including the
102 XML document and all associated image files referenced in the XML document, such as
103 chemical structures or graphs included in a clinical studies section). Other labeling documents
104 (e.g., the annotated labeling, container labels, and carton labels) should not be submitted to the
105 application using the SPL standard.

⁴ See 21 CFR 314.50(l) for NDAs, 314.94(d) for ANDAs, 601.14(b) for BLAs, and 314.81(b) for annual reports.

⁵ See FDA’s guidance *Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing*.

Contains Nonbinding Recommendations

Draft — Not for Implementation

106

107 **5. Should an applicant still submit an annotated Word version of the content of**
108 **labeling?**

109 Yes. We recommend that applicants continue to submit the annotated Word version of the label
110 and all labeling for the product. SPL is the current standard for electronic content of labeling
111 submissions and replaces proposed content of labeling submissions in PDF format.

112 **6. How do I send my SPL file to FDA when making an electronic**
113 **submission?**

114 The SPL file should be included in a folder marked *spl* within the labeling folder. Refer to
115 guidance for industry *Providing Regulatory Submissions in Electronic Format – Content of*
116 *Labeling* for more information on the SPL submission process.

117
118 Alternatively, you can provide the Uniform Resource Locator (URL) to the SPL file for CBEs,
119 annual reports, and final approved labeling if the SPL labeling was already submitted during the
120 electronic registration and listing process.

121

122 **7. How do I send my SPL file to FDA if my submission is in paper format?**

123 When accompanying a submission in paper format, the SPL file should be submitted using
124 electronic media (e.g., CD-ROM). The SPL should be included in a folder marked *spl* (see
125 guidance for industry *Providing Regulatory Submissions in Electronic Format – Content of*
126 *Labeling*).

127 **8. Where do I send my SPL submission?**

128 For products regulated by CDER, see <http://www.fda.gov/cder/regulatory/ersr/default.htm>, for
129 the address to send electronic submissions. For products regulated by CBER, see
130 <http://www.fda.gov/CBER/regsopp/8110.htm>. Consult www.fda.gov/esg for submissions via the
131 Electronic Submissions Gateway for both CDER and CBER regulated products.

132 **9. When did CDER and CBER begin accepting SPL for content of labeling?**

133 CDER began accepting content of labeling in SPL format in September 2004. At that time,
134 CDER accepted content of labeling submissions in both SPL and PDF and announced that
135 CDER would begin accepting only SPL beginning in the autumn of 2005. Since October 31,
136 2005, CDER has been accepting content of labeling submissions only in SPL format. CBER
137 began accepting content of labeling exclusively in SPL format on October 15, 2008, as noted
138 in the memorandum to the electronic submissions docket, published on July 11, 2008.

139 **10. Should ANDA applicants wait for submission of content of labeling for the**
140 **reference listed drug (RLD) before they submit content of labeling in SPL format?**

141 No. If an ANDA applicant determines that content of labeling has not been submitted in SPL

Contains Nonbinding Recommendations

Draft — Not for Implementation

142 format for the reference listed drug, the ANDA applicant should still submit its own content of
143 labeling in SPL format.

144 **11. Can the electronic labeling be submitted under separate cover and cross-**
145 **referenced to a paper submission for all types of submissions, including new ANDAs,**
146 **supplements, and annual reports, or should the entire submission be done electronically?**

147 Yes, a combination of electronic labeling for the content of labeling and paper application
148 submission would be appropriate.

149 **12. Does the SPL content of labeling replace the 12 copies of paper labeling,**
150 **also known as final printed labeling (FPL), that are normally submitted with an**
151 **application?**

152 The requirement under 21 CFR 314.50 (l)(i) to provide content of labeling in electronic form
153 is in addition to the obligation to submit copies of the label and all labeling, including 12
154 paper copies of FPL, as required by section 314.50(e)(2)(ii) . See also 314.94(d)(i)(ii)
155 (ANDAs) and 601.14(b)(2) (BLAs). Applicants should submit either 12 paper copies or 1
156 PDF copy of FPL carton and container labels, but should submit only SPL files for the
157 content of labeling submitted with an application.

158 **13. If the content of labeling is approved based on the draft SPL, when should the final**
159 **SPL be submitted after approval?**

160
161 The final SPL should be submitted preferably within 14 calendar days after approval or as soon
162 as possible thereafter.

163
164 **14. Can we e-mail SPL to the Agency?**

165
166 No. SPL should be submitted either to FDA's Electronic Document Room with documentation
167 appropriate for the type of electronic submission or during the registration and listing process
168 (see response to Question 7).

169
170 **15. Should I submit content of labeling in Word and/or PDF with the SPL?**

171
172 You should no longer submit content of labeling in PDF. However, we recommend that you
173 continue to submit content of labeling in Word. The Word files facilitate the exchange of
174 labeling comments and revisions between the applicant and FDA.

175 **16. Where should I submit SPL files if the application contains both paper and**
176 **electronic components?**

177 Both components of the application should be sent to the relevant center's central
178 document room (just as before implementation of SPL). Similarly, as before
179 implementation of SPL, the staff will upload the electronic component.

Contains Nonbinding Recommendations

Draft — Not for Implementation

180 **17. Should companies resubmit labeling in SPL if it was submitted before October**
181 **15, 2008, in another format and is currently under review in CBER?**

182 No, but we recommend that applicants work with the individual review division or divisions to
183 ensure that SPL is available within a reasonable time frame for those products with submissions
184 before October 15, 2008.

185 **18. Can FDA refuse to file my submission if I do not provide SPL, given that I am**
186 **required to do so?**

187 Yes, but we will work with you to help you submit the SPL.

188 **19. What software do I use to create SPL files?**

189 An SPL file can be created using a variety of tools, ranging from a general-purpose word
190 processor or XML editor to an SPL-specific editing tool. The type of tool suitable for a specific
191 organization will vary depending on a wide variety of business and technical factors. Whatever
192 tool is used, the final SPL document will be independent of the tool used for its creation. All
193 tools should be able to create valid SPL files and to conform to the guidance for industry
194 *Providing Regulatory Submissions in Electronic Format – Content of Labeling*.

195 **20. What is the difference between XML and SPL?**

196 XML is a specification for creating custom markup languages for sharing structured data. SPL is
197 a standard that uses XML.

198
199 **21. What version of the SPL schema is currently being used by FDA?**

200 The SPL schema currently being used is identified on the FDA Data Standards Council
201 Web site located at www.fda.gov/oc/datacouncil.

202 **22. What happens when a new release of the SPL standard is implemented? Should I**
203 **resubmit current labels according to the schema in the new release?**

204 We have implemented SPL release 4 to be compatible with the drug registration and
205 listing process. SPL files can be submitted using the schema in SPL release 4 or release 3
206 until June 1, 2009, when only release 4 can be used.

207 **23. Should I submit patient package inserts (PPIs) and Medication Guides (MGs)**
208 **in SPL?**

209 Approved patient labeling documents should be included at the end of the SPL file. There are
210 specific Logical Observation Identifiers Names and Codes (LOINC) codes for PPIs and MGs.
211 Use the appropriate LOINC code for identifying this information. Each PPI or MG should have
212 a separate LOINC code.

Contains Nonbinding Recommendations

Draft — Not for Implementation

213 Patient information that is not approved labeling, such as patient information produced by
214 third parties, should not be included in the SPL file.

215 **24. Should my SPL file contain the entire content of labeling or just the portion of**
216 **the content that has changed since my last application submission?**

217 All submissions should include the entire content of labeling in SPL. FDA cannot support partial
218 submissions at this time.

219 **25. The SPL standard provides tags to identify insertions and deletions of content in**
220 **an SPL document. Should I submit a redlined or annotated version of the labeling,**
221 **indicating version-to-version changes?**

222 No. You should not use the tags provided in the SPL standard to mark up the insertion and
223 deletion of content.

224
225 **26. Should I include graphics for controlled substance symbols, the Rx symbol or**
226 **corporate or product logos?**

227 No. These graphics should not be included in an SPL submission. Controlled substance symbols,
228 and other symbols, should be included in the SPL as text (e.g., CII).

229 **27. Can I retain hypertext links within a document if they were present in a Word or**
230 **PDF file of content of labeling (e.g., clickable cross-references)?**

231 Yes. Hypertext links can be retained within the SPL document. However, these links should
232 correspond only to other portions of the content of labeling, (e.g., see *Dosage and*
233 *Administration* (2)).

234 **28. Does the FDA distribute SPL documents to the Web with minor changes to the**
235 **section identifiers submitted?**

236 Yes, at the moment, we correct certain coding omissions and errors. However, when applicants
237 begin using SPL release 4, we will no longer make these corrections.

238 **29. In preparing an SPL, should I update the section identifier when there is a change**
239 **in a subsection?**

240 Yes.

241 **30. If I relocate a section or subsection without changing its content, should its**
242 **section identifier be changed?**

243 No. The identifier of a section that is relocated without content change remains unchanged, but
244 the identifiers of any enclosing sections before and/or after the relocation should be changed, as
245 should the document identifier.

Contains Nonbinding Recommendations

Draft — Not for Implementation

246

247 **31. How is labeling information transmitted to the Web?**

248 Beginning June 1, 2009, FDA will transmit postapproval SPL to the Web electronically from the
249 electronic drug establishment registration and drug listing system, which will then be considered
250 the key repository for postmarket SPL content of labeling. Labeling updates to applications can
251 be made by referencing the SPL file submitted through the drug establishment registration and
252 drug listing process (see question 3 for the Web address).

253 **32. If an applicant identifies a problem with the SPL file posted on the Web site,
254 what should he or she do?**

255 If an applicant notes an inconsistency, he or she should contact the SPL coordinator at
256 spl@fda.hhs.gov and the relevant center's review division to make the necessary changes.

257 **33. When is SPL transmitted to the Web and will FDA notify the applicant when SPL is
258 posted?**

259 No. There is no notification to the applicant that labeling has been posted. Applicants are advised
260 to check the Web site to ensure that their most recently submitted content of labeling is posted.

261 **34. Should an applicant submit SPL with an annual report?**

262 Applicants should submit an SPL file of the content of labeling with an annual report if an SPL
263 file has not previously been submitted for the application, or if there have been changes to the
264 content of labeling since the last submission of final SPL. If there have been no changes since
265 the last submission of final SPL, then the annual report can include a reference to the electronic
266 content of labeling previously submitted.⁶

267

268 **35. If the first SPL submission is a supplement, should both the current and proposed
269 labeling be submitted in SPL, or is it sufficient to submit the proposed labeling in SPL?**

270 For supplements, only the proposed content of labeling should be submitted in SPL. In addition,
271 annotated labeling should also be submitted for use in the application review process. (See
272 response to Question 5).

273 **36. Where do I find additional information and specifications on SPL?**

274 Additional information is available on the Internet at the FDA Data Standards Council Web
275 site and <http://www.hl7.org>.

⁶ Final SPL is the submission of SPL that is in current use. This includes SPL with approved content of labeling submitted subsequent to the approval of an original BLA/NDA or prior approval supplement; SPL submitted to a CBE supplement (with the initial submission and any subsequent amendments); and SPL submitted to an annual report that contains "annual reportable" changes made since the last submission of final SPL.

Contains Nonbinding Recommendations

Draft — Not for Implementation

276 **37. Should content of labeling in a foreign language be submitted?**

277 Currently, foreign language content of labeling does not need to be submitted in SPL.